---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "3W/qhr6ldko2zxi6S4b3qo4BcDFzlG05SoJew/01N8/5VnqCSn88gKOuhql01iknEnU8L1lpioio0pQSHceTpqU9PtK9zf94EUi4BsPo1M6F7p1vf0pPopFm3WfxWZ9nXaBksF/hff6NWG0t28+HT5FXHHNsv55KwEeTnKCOADq6CcsejdvyylRq4dmnzvu9SXSZ02kSzNtbyaTsXPDKYP+CHfS2P+qBGQ6OvCWBd1QilCcJ5y6ZszIhScx3GI02xkPK2DL0xFerMb4TtdApNJJChlX11t9SRbwxzIAUMLpNbQ9DhX5f6pr5QD8uz+daRcNK1tFbvdP9ASNeEkkEFfjls/q7jb/bkIfP8BaGRrk=;x6LwpHvFW9M3uiuTPhFB/A=="
---

